Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Total Liabilities (2016 - 2025)

Immucell (ICCC) has disclosed Total Liabilities for 16 consecutive years, with $15.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 11.69% year-over-year to $15.9 million, compared with a TTM value of $15.9 million through Sep 2025, down 11.69%, and an annual FY2024 reading of $17.6 million, down 6.55% over the prior year.
  • Total Liabilities was $15.9 million for Q3 2025 at Immucell, down from $16.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $18.8 million in Q4 2023 and bottomed at $11.5 million in Q2 2021.
  • Average Total Liabilities over 5 years is $15.5 million, with a median of $15.9 million recorded in 2025.
  • The sharpest move saw Total Liabilities grew 29.93% in 2023, then fell 11.69% in 2025.
  • Year by year, Total Liabilities stood at $11.9 million in 2021, then rose by 21.8% to $14.5 million in 2022, then rose by 29.93% to $18.8 million in 2023, then decreased by 6.55% to $17.6 million in 2024, then fell by 9.4% to $15.9 million in 2025.
  • Business Quant data shows Total Liabilities for ICCC at $15.9 million in Q3 2025, $16.9 million in Q2 2025, and $16.6 million in Q1 2025.